A new three-year £180m programme has been launched by the Technology Strategy Board and the Medical Research Council, to support life science companies and academia.
The programme, named the Biomedical Catalyst fund, is designed to help companies more more quickly from discovery to commercialisation. Support will be available for both academically- and commercially-led R&D.
“We are particularly keen to help SMEs to engage more with clinical proof of concept studies, where partnerships with academic research groups and patient participation are vital,” comments Sir John Savill, CEO of the Medical Research Council.
The Biomedical Catalyst fund will provide staged investment, while also allowing applications that are already partly developed to enter the “pathway” at any suitable stage.
“It will provide a well publicised, simple funding scheme, with rigorous scientific, clinical and commercial tests, that gives credibility and visibility to help companies to move more quickly to commercial success, revenues and sustainability,” says the Technology Strategy Board.
Share this story